

Chair: Donal McLornan

Secretaries: Joanna Drozd-Sokolowska & Kavita Raj

Data management: Linda Koster, Laurien Baaij, Joe Tuffnell


Statisticians: Dirk-Jan Eikema, Luuk Gras, Simona Iacobelli

## Ongoing studies - highlights

- Impact of Specific Adverse Cytogenetic Features on Outcomes after Allo HCT in MDS with Very Poor Risk Cytogenetics (Xavier Poiré)
- Allo-HCT in CLL after multiple pathway inhibitors (Michel van Gelder/ Olivier Tournilhac)
- Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Auto HCT in EBMT Centres (Patrick Hayden)


## MDS

Chair: Marie Robin, Vice Chair: Christof Scheid & Carmelo Gurnari & Francesco Onida




## PCD

Chair: Patrick Hayden, Vice Chair: Meral Beksac & Stefan Schönland




## CML

Chair: Yves Chalandon, Vice Chair: Guillermo Ortí & Hugues De Lavallade




## MPN

Chair: Juan Carlos Hernández-Boluda, Vice Chair: Tomasz Czerw & Nicola Polverelli & Giorgia Battipaglia




## MDS/MPN

Chair: Marie Robin, Vice Chair: Christof Scheid & Carmelo Gurnari & Francesco Onida




## PCD CAR-T

Chair: Nico Gagelmann, Vice Chair: Laurent Garderet



## CLL

Chair: Olivier Tournilhac, Vice Chair: Michel van Gelder



## Published in 2024

Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee – *McLornan et al. Leukemia. 2024 Apr;38(4):699-711.*

Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for Myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT – *Robin et al. Bone Marrow Transplant. 2024 Jul;59(7):928-935.*

Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation – *Garderet et al. Haematologica. 2024 Aug 1;109(8):2619-2627.*

Mismatched Related Donor Allogeneic Hemopoietic Cell Transplantation Compared to other Donor Types for Ph+ Chronic Myeloid Leukemia: a Retrospective Analysis from the Chronic Malignancies Working Party of the EBMT – *Onida et al. Br J Haematol. 2024 Jun;204(6):2365-2377.*

Reduced Intensity versus Myeloablative Conditioning for MDS: Longterm Results of an EBMT Phase III Study (RICMAC) – *Niederwieser et al. Bone Marrow Transplant. 2024 Aug;59(8):1084-1091.*

Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms? – *Scheid et al. Blood. 2024 Jul 25;144(4):445-456.*

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee – *Onida et al. Blood. 2024 May 30;143(22):2227-2244.*

Unrelated donor transplantation with posttransplant cyclophosphamide versus ATG for myelodysplastic neoplasms – *Chalandon et al. Blood Adv. 2024 Sep 24;8(18):4792-4802.*

Global Characteristics and Outcomes of Autologous Hematopoietic Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: A Study of The Worldwide Network for Blood and Marrow Transplantation (WBMT) – *Garderet et al. Am J Hematol. 2024 Nov;99(11):2084-2095.*

Navigating 'Grey areas' and Challenges during Evaluation of Transplant Eligibility in Specific Myelofibrosis Populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT – *Polverelli et al. Bone Marrow Transplant. 2025 Jan;60(1):10-18.*

Evaluation and management of hepatic dysfunction, portal hypertension and portal/splanchnic vein thrombosis in patients with myelofibrosis undergoing allogeneic haematopoietic cell transplantation: A practice based survey on behalf of the Chronic Malignancies Working Party of the EBMT – *Battipaglia et al. Curr Res Transl Med. 2024 Oct 25;73(1):103476.*

Allogeneic Hematopoietic Cell Transplantation for Therapy-related Myeloid Neoplasms arising following treatment for Multiple Myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT – *Raj et al. Bone Marrow Transplant. 2024 Nov 12.*

Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT – *Sever, Drozd-Sokolowska et al. Bone Marrow Transplant. 2024 Nov 12.*

Methotrexate versus Mycophenolate Mofetil prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: a retrospective analysis on behalf of the Chronic Malignancies Working Party of the EBMT – *Luft et al. Am J Hematol. 2025 Jan;100(1):38-51.*

## Warsaw meeting 2024

